These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11355589)

  • 41. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Vikram B
    J Clin Oncol; 2001 Feb; 19(4):1233-4. PubMed ID: 11181692
    [No Abstract]   [Full Text] [Related]  

  • 42. [Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer].
    Grötz KA; Henneicke-von Zepelin HH; Kohnen R; al-Nawas B; Bockisch A; Kutzner J; Wüstenberg P; Naser-Hijazi B; Belz GG; Wagner W
    Strahlenther Onkol; 1999 Aug; 175(8):397-403; discussion 404. PubMed ID: 10481772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity.
    Pfeiffer P; Hansen O; Madsen EL; May O
    Acta Oncol; 1990; 29(4):471-3. PubMed ID: 2390274
    [No Abstract]   [Full Text] [Related]  

  • 44. Glutamine in Alleviation of Radiation-Induced Severe Oral Mucositis: A Meta-Analysis.
    Leung HW; Chan AL
    Nutr Cancer; 2016 Jul; 68(5):734-42. PubMed ID: 27045857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoprotection in head and neck cancer: issues in oral care.
    Samuels MA
    J Support Oncol; 2004; 2(6 Suppl 3):9-12. PubMed ID: 15605919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
    Anné PR; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
    Messerschmidt GL; Oleka N
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effect of Cepharanthin to prevent radiation induced xerostomia in head and neck cancer].
    Imada H; Nomoto S; Ohguri T; Yahara K; Kato F; Morioka T; Korogi Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1041-5. PubMed ID: 15272582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
    Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies.
    Hong JP; Lee SW; Song SY; Ahn SD; Shin SS; Choi EK; Kim JH
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):636-41. PubMed ID: 19456848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cepharanthin effect on radiation-induced xerostomia and taste disorder in patients with head and neck cancer].
    Shimazu R; Tanaka G; Tomiyama R; Kuratomi Y; Inokuchi A
    Nihon Jibiinkoka Gakkai Kaiho; 2009 Sep; 112(9):648-55. PubMed ID: 19860267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
    Mell LK; Movsas B
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sucralfate in radiation-induced mucositis.
    Sur RK
    S Afr Med J; 1997 Mar; 87(3):337-8. PubMed ID: 9137350
    [No Abstract]   [Full Text] [Related]  

  • 57. Randomized double-blind, placebo-controlled trial evaluating oral glutamine on radiation-induced oral mucositis and dermatitis in head and neck cancer patients.
    Huang CJ; Huang MY; Fang PT; Chen F; Wang YT; Chen CH; Yuan SS; Huang CM; Luo KH; Chuang HY; Wang YY; Lee HH
    Am J Clin Nutr; 2019 Mar; 109(3):606-614. PubMed ID: 30753262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma.
    Kannan V; Bapsy PP; Anantha N; Doval DC; Vaithianathan H; Banumathy G; Reddy KB; Kumaraswamy SV; Shenoy AM
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1005-10. PubMed ID: 9169806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.